Tech Transfer eNews Blog

U of Dundee inks license for new multiple sclerosis drug target  

By Jesse Schwartz
Published: June 12th, 2019

The University of Dundee has licensed out rights to research to Corbin Therapeutics, a Montreal-based biotech company, that could lead to new treatments for neuroinflammation-based disorders such as multiple sclerosis (MS).

The licensed technology is focused on USP15, a ubiquitin-specific protease that has shown to be crucial in the pathogenesis of neuroinflammation. Corbin aims to harness the research to identify and validate novel small molecule inhibitors of USP15 that could eventually be developed into treatments for MS and other diseases of the central nervous system.

The license agreement builds on the existing research and development partnership between Corbin and the University of Dundee’s Drug Discovery Unit. Through this partnership, which is supported by funding from the UK Medical Research Council, the university and Corbin have delivered a range of drug-like compounds for clinical development.

“We are committed to the translation of world-class biology into novel drug targets and candidate drugs, and we work with partners globally to achieve this,” says Julie Brady, business development manager for the Drug Discovery Unit. “The relationship with Corbin has created a transatlantic, multidisciplinary team working towards the discovery of new medicines for diseases associated with neuroinflammation.”

Sean MacDonald, CEO of Corbin, comments, “The team in Dundee have helped us move forward with a very promising discovery program targeting USP15. Corbin is now focused on developing novel drugs that have the potential to treat a number of diseases of unmet medical need and to deliver value for our shareholders.”

Sources: EurekAlert!

Posted under: Tech Transfer e-News

Twitter Facebook Linkedin Pinterest Email

No Comments so far ↓

There are no comments yet...Kick things off by filling out the form below.

Leave a Comment